Suzhou city, Jiangsu province-based Chinese bio-pharmaceutical firm Innovent Biologics, Inc. has raised US$100 million series C financing led by Legend Capital, according to a company announcement. New investors, Singapore's Temasek Holdings and two unnamed investors, as well as existing investors Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures, and Frontline Bioventures, also participated. The […]
Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.